AMYRA Biotech

Executive Summary

AMYRA Biotech is a Swiss private biotechnology company founded in 2018 and headquartered in Zug, Switzerland. The company is pioneering innovative enzyme therapies for celiac disease and gluten sensitivity through its proprietary BBEST (Bypass, Block, Enhance, Stabilize, Transport) platform. Celiac disease affects approximately 1% of the global population, with no approved pharmacotherapies beyond a strict gluten-free diet. AMYRA's approach aims to degrade gluten in the gastrointestinal tract, potentially allowing patients to tolerate accidental gluten exposure and improve quality of life. The company's lead candidate is designed to be administered orally and act locally in the gut, leveraging a novel combination of enzymes engineered for stability and activity under digestive conditions. By targeting the root cause of gluten immunotoxicity, AMYRA could address a significant unmet medical need and capture a substantial market opportunity. The company is at a preclinical-to-early clinical stage, with plans to initiate first-in-human studies in the near term.

Upcoming Catalysts (preview)

• Q3 2026Advancement of lead candidate into Phase 1 clinical trials60% success
• H2 2026Strategic partnership or licensing agreement for BBEST platform40% success
• Q4 2026Series B or later-stage funding round to support clinical development50% success